Filing Details
Marker Therapeutics, Inc. (NASDAQ:MRKR) filed a Form 8-K with the Securities and Exchange Commission on October 19, 2026, disclosing a material event.
8k filedNASDAQ:MRKR
Marker Therapeutics, Inc. (MRKR) Reports Material Event to SEC
Marker Therapeutics, Inc. (NASDAQ:MRKR) filed a Form 8-K with the Securities and Exchange Commission on October 19, 2026, disclosing a material event.
At publication ·
What changed
Marker Therapeutics, Inc. (NASDAQ:MRKR) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Marker Therapeutics filed a Form 8-K on October 19, 2026, disclosing a material event to shareholders.
- The company's stock trades at $1.20 with a market capitalization of $15.4 million.
- Form 8-K filings report significant events such as leadership changes, agreements, acquisitions, or asset sales between regular reports.
Market Context
Marker Therapeutics, Inc.'s stock currently trades at $1.20 with a market capitalization of $15.4M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Marker Therapeutics, Inc.'s stock.
All SEC filings for Marker Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View MRKR Stock Page
Frequently Asked Questions
Where can I read MRKR's SEC filings?
Browse all filings on our MRKR SEC filings page.
What types of SEC filings does Marker Therapeutics, Inc. file?
Public companies like Marker Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.